Tekmira, USAMRIID Publish Data Showing Ebola Protection in Primates Using SNALP RNAi Rx | GenomeWeb

By Doug Macron

Tekmira Pharmaceuticals last week announced the publication of data showing that the company's proprietary nucleic acid-delivery technology could be used in conjunction with an RNAi drug to protect non-human primates from a lethal dose of Ebola virus.

The data, Tekmira President and CEO Mark Murray said in a statement, "are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting," and support the utility of RNAi in infectious diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.